These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8603335)

  • 1. Acquisition of doxorubicin resistance in human leukemia HL-60 cells is reproducibly associated with 7q21 chromosomal anomalies.
    Ganapathi R; Hoeltge G; Casey G; Grabowski D; Neelon R; Ford J
    Cancer Genet Cytogenet; 1996 Feb; 86(2):116-9. PubMed ID: 8603335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Karyotypic imbalances and differential gene expressions in the acquired doxorubicin resistance of hepatocellular carcinoma cells.
    Pang E; Hu Y; Chan KY; Lai PB; Squire JA; Macgregor PF; Beheshti B; Albert M; Leung TW; Wong N
    Lab Invest; 2005 May; 85(5):664-74. PubMed ID: 15765123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity.
    David-Beabes GL; Overman MJ; Petrofski JA; Campbell PA; de Marzo AM; Nelson WG
    Int J Oncol; 2000 Dec; 17(6):1077-86. PubMed ID: 11078791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells.
    Huang Y; Ibrado AM; Reed JC; Bullock G; Ray S; Tang C; Bhalla K
    Leukemia; 1997 Feb; 11(2):253-7. PubMed ID: 9009089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines.
    Consoli U; Priebe W; Ling YH; Mahadevia R; Griffin M; Zhao S; Perez-Soler R; Andreeff M
    Blood; 1996 Jul; 88(2):633-44. PubMed ID: 8695811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytogenetic and molecular characterization of random chromosomal rearrangements activating the drug resistance gene, MDR1/P-glycoprotein, in drug-selected cell lines and patients with drug refractory ALL.
    Knutsen T; Mickley LA; Ried T; Green ED; du Manoir S; Schröck E; Macville M; Ning Y; Robey R; Polymeropoulos M; Torres R; Fojo T
    Genes Chromosomes Cancer; 1998 Sep; 23(1):44-54. PubMed ID: 9713996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.
    Ross DD; Doyle LA; Yang W; Tong Y; Cornblatt B
    Biochem Pharmacol; 1995 Nov; 50(10):1673-83. PubMed ID: 7503771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversing Multidrug Resistance in Chemo-resistant Human Lung Adenocarcinoma (A549/DOX) Cells by Algerian Propolis Through Direct Inhibiting the P-gp Efflux-pump, G0/G1 Cell Cycle Arrest and Apoptosis Induction.
    Kebsa W; Lahouel M; Rouibah H; Zihlif M; Ahram M; Abu-Irmaileh B; Mustafa E; Al-Ameer HJ; Al Shhab M
    Anticancer Agents Med Chem; 2018; 18(9):1330-1337. PubMed ID: 30088453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Messenger RNA expression of resistance proteins and related factors in human ovarian carcinoma cell lines resistant to doxorubicin, taxol and cisplatin.
    Masanek U; Stammler G; Volm M
    Anticancer Drugs; 1997 Feb; 8(2):189-98. PubMed ID: 9073315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
    Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
    Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of P-glycoprotein and alterations in topoisomerase II in P388 mouse leukemia cells selected in vivo for resistance to mitoxantrone.
    Kamath N; Grabowski D; Ford J; Kerrigan D; Pommier Y; Ganapathi R
    Biochem Pharmacol; 1992 Sep; 44(5):937-45. PubMed ID: 1356339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ability of selected pyridinium salts to increase the cytotoxic activity of vincristine but not doxorubicin towards sensitive and multidrug resistant promyelocytic leukaemia HL60 cells.
    Maruszewska A; Kostrzewa-Nowak D; Adamus J; Czupryńska K; Maryniak D; Gebicki J; Tarasiuk J
    J Pharm Pharmacol; 2008 May; 60(5):647-53. PubMed ID: 18416942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic 1,4-anthracenediones, which block nucleoside transport and induce DNA fragmentation, retain their cytotoxic efficacy in daunorubicin-resistant HL-60 cell lines.
    Wu M; Wang B; Perchellet EM; Sperfslage BJ; Stephany HA; Hua DH; Perchellet JP
    Anticancer Drugs; 2001 Nov; 12(10):807-19. PubMed ID: 11707648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doxorubicin selected multidrug-resistant small cell lung cancer cell lines characterised by elevated cytoplasmic Ca2+ and resistance modulation by verapamil in absence of P-glycoprotein overexpression.
    Nygren P; Larsson R; Gruber A; Peterson C; Bergh J
    Br J Cancer; 1991 Dec; 64(6):1011-8. PubMed ID: 1684906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.
    Stein U; Lage H; Jordan A; Walther W; Bates SE; Litman T; Hohenberger P; Dietel M
    Int J Cancer; 2002 Feb; 97(6):751-60. PubMed ID: 11857350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A synthetic triptycene bisquinone, which blocks nucleoside transport and induces DNA fragmentation, retains its cytotoxic efficacy in daunorubicin-resistant HL-60 cell lines.
    Wang B; Wu M; Perchellet EM; McIlvain CJ; Sperfslage BJ; Huang X; Tamura M; Stephany HA; Hua DH; Perchellet JP
    Int J Oncol; 2001 Dec; 19(6):1169-78. PubMed ID: 11713586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Pgp activity and cell cycle-dependent chemosensitivity to doxorubicin in the multidrug-resistant LoVo human colon cancer cell line.
    Toffoli G; Corona G; Gigante M; Boiocchi M
    Eur J Cancer; 1996 Aug; 32A(9):1591-7. PubMed ID: 8911123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S9788 modulation of P-glycoprotein- and Multidrug-related protein-mediated multidrug resistance by Servier 9788 in doxorubicin-resistant MCF7 cells.
    Bichat F; Solis-Recendez G; Poullain MG; Poupon MF; Khayat D; Bastian G
    Biochem Pharmacol; 1998 Aug; 56(4):497-502. PubMed ID: 9763226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation between MDR1 mRNA levels, resistance factor, and the efficiency of P-glycoprotein-mediated efflux of pirarubicin in multidrug-resistant K562 sublines.
    Meesungnoen J; Jay-Gerin JP; Mankhetkorn S
    Can J Physiol Pharmacol; 2002 Nov; 80(11):1054-63. PubMed ID: 12489924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines.
    Kostrzewa-Nowak D; Paine MJ; Wolf CR; Tarasiuk J
    Br J Cancer; 2005 Jul; 93(1):89-97. PubMed ID: 15942634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.